ARIAD Confirms Receipt of Sarissa Capital Management’s Nomination of Director Candidates
February 20 2015 - 9:23AM
Business Wire
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today confirmed that
it has received notice of nomination by Sarissa Capital Management
LP of two director candidates for election at the 2015 Annual
Meeting. ARIAD has no further comment at this time.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts and Lausanne, Switzerland, is an integrated global
oncology company focused on transforming the lives of cancer
patients with breakthrough medicines. ARIAD is working on new
medicines to advance the treatment of various forms of chronic and
acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer
medicines. For additional information, visit http://www.ariad.com
or follow ARIAD on Twitter (@ARIADPharm).
ARIAD Pharmaceuticals, Inc.For InvestorsKendra Adams,
617-503-7028Kendra.adams@ariad.comorFor MediaLiza Heapes,
617-621-2315Liza.heapes@ariad.comorSard Verbinnen & Co.George
Sard/Andrew Cole/Chris Kittredge, 212-687-8080
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Oct 2023 to Oct 2024